Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

Foley, James E

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. [electronic resource] - Vascular health and risk management Aug 2010 - 541-8 p. digital

Publication Type: Journal Article; Review

1178-2048

10.2147/vhrm.s10952 doi


Adamantane--analogs & derivatives
Blood Glucose--analysis
Body Weight--drug effects
Diabetes Mellitus, Type 2--drug therapy
Dipeptidyl-Peptidase IV Inhibitors--pharmacology
Glucose--metabolism
Humans
Hypoglycemic Agents--adverse effects
Insulin Resistance
Nitriles--pharmacology
Pyrrolidines--pharmacology
Vildagliptin
Weight Gain--drug effects